← Leaderboards
Craig J Burd
Ohio State University
$3,860,523
Attributed
$3,860,523
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $707.1K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,860,523 · 3
By mechanism
R01$3,131,062 · 2
R00$729,461 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- William E. Carson$27,905,247
- Anna E Vilgelm$2,524,271
- Pan Zheng$7,391,253
- Juan D Alfonzo$5,198,208
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsWomanExhibitsSignal TransductionEstrogensPlayExposure ToClinical ResearchMediatingGeneticMolecularLinkMouse ModelBiologyHormonesMalignant Breast NeoplasmBiologicalAnimal ModelBiochemicalBreastBisphenol AEpigenetic ProcessEventEndocrine Disruptors
Grant awards (12)
Estrogen receptor beta is a targetable melanoma tumor suppressor$356,540
R01 · FY2025 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$350,530
R01 · FY2025 · ES · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$350,747
R01 · FY2024 · ES · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$333,894
R01 · FY2024 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$345,531
R01 · FY2023 · ES · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$344,926
R01 · FY2023 · CA · contact PI
Estrogen receptor beta is a targetable melanoma tumor suppressor$356,359
R01 · FY2022 · CA · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$346,031
R01 · FY2022 · ES · contact PI
Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk$346,504
R01 · FY2021 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$237,246
R00 · FY2015 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$243,215
R00 · FY2014 · ES · contact PI
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor Function$249,000
R00 · FY2013 · ES · contact PI